New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 — The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
FDA Approves Kisunla (Donanemab) | Alzheimer's Association
WEBCHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab
WEBJun 11, 2024 — On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of...
Experimental Alzheimer's drug donanemab outperforms Leqembi in ... - NPR
WEBJul 17, 2023 — In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July...
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer…
WEBJul 2, 2024 — The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla - AP News
WEBJul 2, 2024 — The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.
FDA approves treatment for adults with Alzheimer’s disease
WEBJul 2, 2024 — The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with...
The Next Potential Alzheimer’s Drug Clears a Big Hurdle
WEBJun 11, 2024 — A panel of brain and Alzheimer’s experts convened by the U.S. Food and Drug Administration (FDA) voted unanimously on June 10 that a new Alzheimer’s drug developed by Eli Lilly, called...
FDA Advisory Committee Agrees on Donanemab Efficacy | alz.org
WEBJun 10, 2024 — The Alzheimer’s Association welcomes the advisory committee’s unanimous finding that donanemab is effective for the treatment of early Alzheimer’s disease. If approval is granted by the FDA, donanemab will be the second traditional approval of an Alzheimer’s treatment to change the underlying course of the disease.
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab …
WEBJul 17, 2023 — Eli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer’s treatment, donanemab, and expects the agency to make a decision by the end of the year ...